Aadi Bioscience to Present at 2022 H.C. Wainwright BioConnect Virtual Conference

Rhea-AI Summary

Aadi Bioscience, a biopharmaceutical firm, announced that its CEO, Neil Desai, Ph.D., will present at the H.C. Wainwright BioConnect Conference from January 10-13, 2022. The presentation will be accessible starting January 10 at 7:00 a.m. ET. Aadi focuses on precision therapies for genetically-defined cancers, especially those with mTOR pathway alterations. After receiving FDA approval for FYARRO, an mTOR inhibitor for treating PEComa, the company plans to initiate a tumor-agnostic trial in 2022 and further studies on FYARRO's dosing in combination regimens.

LOS ANGELES, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”), a biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that Founder, Chief Executive Officer and President, Neil Desai, Ph.D., will present at the H.C. Wainwright BioConnect Conference, to be held virtually January 10-13, 2022. The presentation will be available beginning on Monday, January 10, 2022 at 7:00 a.m. ET.

The webcast can be accessed here. A replay will also be available on Aadi’s website within the News/Events & Presentations section.

About Aadi Bioscience

Aadi is a commercial-stage biopharmaceutical company focused on precision therapies for genetically-defined cancers. Aadi’s primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. In November 2021, Aadi received FDA approval for FYARRO for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). FYARRO is an mTOR inhibitor bound to human albumin that has demonstrated significantly higher tumor accumulation, greater mTOR target suppression, and increased tumor growth inhibition over other mTOR inhibitors in preclinical models.

Based on data from the AMPECT trial with FYARRO and following discussions with the FDA about other emerging data with FYARRO, Aadi plans to initiate a tumor-agnostic registrational trial in mTOR inhibitor-naïve solid tumors harboring TSC1 or TSC2 inactivating alterations by early 2022. Aadi also has ongoing studies to evaluate dosing of FYARRO in combination regimens. More information on Aadi’s development pipeline is available on the Aadi website at www.aadibio.com.

Contacts:

Investors

Irina Koffler
ikoffler@lifesciadvisors.com

FAQ

When will Aadi Bioscience present at the H.C. Wainwright BioConnect Conference?

Aadi Bioscience will present at the H.C. Wainwright BioConnect Conference from January 10-13, 2022, with the presentation available starting January 10 at 7:00 a.m. ET.

What is FYARRO and what is it used for?

FYARRO is an mTOR inhibitor that Aadi Bioscience received FDA approval for, used to treat adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).

What are Aadi Bioscience's plans for FYARRO in 2022?

In 2022, Aadi Bioscience plans to initiate a tumor-agnostic registrational trial for mTOR inhibitor-naïve solid tumors with TSC1 or TSC2 inactivating alterations.

Where can I find more information about Aadi Bioscience's development pipeline?

More information about Aadi Bioscience's development pipeline can be found on their website at www.aadibio.com.